12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280] Technology appraisal guidance 5 February 2025 Abaloparatide for treating ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

There is a simple discount patient access scheme for vadadustat. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact enquiries@medice ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the vadadustat being ...

The evaluation committee considered evidence submitted by MEDICE, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

Tools to help you put the guidance into practice.

Vadadustat is recommended, within its marketing authorisation, as an option for treating symptomatic anaemia caused by chronic kidney disease in adults having maintenance dialysis. Vadadustat is only ...

Vadadustat (Vafseo) is available on the NHS. It is a possible treatment for symptomatic anaemia caused by chronic kidney disease in adults having maintenance dialysis. Your healthcare professionals ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

The appraisal committee has prepared final draft guidance (FDG) on Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821] and submitted it to NICE.